Qiagen stock trades in the low $40s as Q2 2026 earnings beat supports outlook
Published on 08/29/2026 at 07:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Qiagen N.V. (ISIN NL0012169213) stock is trading in the low $40s in late August 2026, supported by a modest earnings-per-share beat in Q2 2026 and steady expectations for growth through 2027 as reflected in current analyst consensus tables. As of August 25, 2026, recent quote data show the New York-listed shares closing at $43.65, marking a 4.48 percent gain for that trading session and underscoring a valuation cluster in the mid $40 band for Qiagen stock 1 3.
Q2 2026 earnings beat and revenue scale
Recent consensus-based earnings tables for Qiagen highlight that in Q2 2026, which ended on June 30, 2026, the company delivered earnings per share of $0.62 versus an estimated $0.60, creating an EPS surprise of 3.45 percent for the quarter 1 3. The same grid shows that for Q1 2026, Qiagen generated revenue of $492.32 million, providing a sense of the companys revenue scale heading into mid 2026 1 3. Taken together, these figures point to a business that is still growing while delivering incremental earnings upside, which has likely contributed to the resilience of Qiagen stock in recent sessions.
The consensus overview breaks out historical earnings performance across several quarters. It shows EPS actuals of $0.64 for the quarter ended September 30, 2025, $0.62 for the quarter ended December 31, 2025, $0.54 for Q1 2026, and $0.62 for Q2 2026, compared with estimates of $0.62, $0.62, $0.54, and $0.60 respectively 3. That translates into EPS surprise percentages of 4.07 percent for the September 2025 quarter, 0.13 percent for the December 2025 quarter, 0 percent for Q1 2026, and 3.45 percent for Q2 2026 3. The ability to deliver positive surprises in three of the last four quarters, even if only modestly, is part of the backdrop that investors are weighing as they assess where Qiagen stock should trade through the rest of 2026.
Growth expectations and consensus view
Consensus data compiled for Qiagen also provide a snapshot of how analysts currently expect the company to perform over the next several reporting periods. In the same table that details recent EPS results, the current quarter for Qiagen is associated with a projected performance metric of negative 4.16 percent, while the next quarter carries an expected growth figure of 6.10 percent 1 3. For the full current fiscal year, the same consensus view points to growth of 2.23 percent, with that rate projected to rise to 7.93 percent in the next fiscal year 1 3. This pattern suggests a short term dip followed by a stronger rebound, which can influence how investors value the shares today.
These expectations sit alongside market return comparisons that frame how Qiagen stock has performed relative to a broad US benchmark. Recent performance tables show that on a year to date basis, Qiagen shares have returned minus 3.27 percent, while a large US benchmark index has returned plus 12.65 percent over the same span 11. On a one year basis, the same comparison shows Qiagen at minus 5.72 percent versus plus 18.61 percent for the benchmark 11. The gap of more than 18 percentage points over the past year underscores that, despite recent support from earnings, Qiagen stock has lagged the broader US market, which could be relevant for investors looking at relative value.
Recent trading levels and volatility
Intraday quote data from late August 2026 give additional context on how Qiagen stock has been trading in the market. During the trading session on August 28, 2026, QGEN shares reached a daily high of $43.99 and a low of $43.24, with a quoted price of $43.63 at the time of the snapshot 6. That leaves the stock 0.9 percent above the session low and 0.8 percent below the high in that same trading day 6. The relatively tight intraday range around the mid $40 level aligns with the broader description of Qiagen shares trading in a band centered just above $43 as investors digest recent quarterly results and guidance commentary 1.
Recent news flow has also included legal developments touching on Qiagen. A late August 2026 report on a patent dispute describes a jury outcome related to a case between Qiagen and another life sciences company, with Qiagens US listed shares quoted at $43.11 at the regular close and $43.05 in post market trading in that context 7. While the report highlights the legal dimension for the sector, the modest price move of minus 1.44 percent on the day referenced suggests that the market reaction for Qiagen stock to that specific development was relatively contained 7. For investors, such legal headlines are an additional factor to track alongside earnings and guidance.
Read more
Further coverage of Qiagen stock, Q2 2026 results and guidance
Diagnostic and sample preparation solutions
Qiagen generates its revenue by providing molecular diagnostics, applied testing, pharma and academic customers with tools for sample preparation and testing. Across its portfolio, the company offers consumable kits, instruments and bioinformatics solutions that enable customers to extract and analyze DNA, RNA and other biomolecules from diverse sample types. In recent years, this mix has allowed Qiagen to tap demand from clinical diagnostic workflows and research projects, with the Q1 2026 revenue of $492.32 million forming the baseline from which investors gauge how successfully the company can grow volumes and maintain pricing power going into the second half of 2026 1 3.
Within this portfolio, Qiagen has developed platforms that help laboratories standardize and automate processes, which can improve throughput and reduce variability in test results. This positioning gives the company exposure to trends such as growing use of molecular diagnostics in oncology, infectious disease testing and personalized medicine. For shareholders assessing long term prospects, the interplay between these structural growth drivers and the quarterly figures in the consensus tables, such as the projected 7.93 percent growth in the next fiscal year 1 3, may be as important as any single quarterly earnings surprise. The consistency of revenue contributions from consumables and recurring usage also helps explain why Qiagen stock trades in a relatively established range in the low $40s despite having lagged the broader market over the past year 1 11.
Qiagen stock price context
Qiagen is listed on the New York Stock Exchange under the ticker QGEN, with its shares quoted in US dollars. Recent market data indicate that as of the close on August 25, 2026, the stock finished the regular US trading session at $43.65, representing a 4.48 percent gain on that day 1. Other late August 2026 snapshots show the shares trading between $43.24 and $43.99 in the following session, with a recent indicated price of $43.63 6. These figures put Qiagen stock modestly below the $44 mark while still within a band that prior coverage has described as the mid $40 range 1 6.
From a broader performance perspective, the return data that show a minus 3.27 percent year to date performance for Qiagen versus plus 12.65 percent for a large US benchmark 11 suggest that the stock has underperformed the broader equity market in 2026 even as it has delivered a Q2 2026 EPS beat of $0.02 per share 3. For investors, this combination of modest fundamental outperformance and relative share price underperformance may raise questions about valuation, execution risk and the sustainability of consensus expectations for 2.23 percent growth in the current year and 7.93 percent next year 1 3 11. How those expectations evolve around the next earnings release could be an important determinant of where Qiagen stock trades in the quarters ahead.
Company fact box
Company: Qiagen N.V.
ISIN: NL0012169213
Ticker: QGEN
Exchange: New York Stock Exchange (primary US listing)
Price (as of August 25, 2026, 4:00 p.m. ET): $43.65 USD
Sector / Industry: Life sciences tools and diagnostics
